AURA
Aura Biosciences Inc
NASDAQ · Biotechnology
$5.60
+0.24 (+4.48%)
Open$5.47
Previous Close$5.36
Day High$5.63
Day Low$5.33
52W High$46.48
52W Low$24.97
Volume—
Avg Volume263.4K
Market Cap355.62M
P/E Ratio22.79
EPS$1.38
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+479.6% upside
Current
$5.60
$5.60
Target
$32.46
$32.46
$26.53
$32.46 avg
$55.40
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 444.35M | 423.64M | 422.21M |
| Net Income | 17.80M | 13.08M | 16.40M |
| Profit Margin | 4.0% | 3.1% | 3.9% |
| EBITDA | 20.20M | 21.97M | 19.97M |
| Free Cash Flow | 12.95M | 9.01M | 11.94M |
| Rev Growth | +9.8% | +0.1% | +6.7% |
| Debt/Equity | 1.09 | 1.02 | 0.95 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |